Vaccine development for Alzheimer's disease

Current Pharmaceutical Design

Volumn 12, Issue 33, 2006, Pages 4283-4293

  DaSilva, Kevin A ^a,b   Aubert, Isabelle ^b,c   McLaurin, Jo Anne ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Alzheimer's disease; Amyloid ; AN1792; Encephalitis; Immunotherapy

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-15]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; DNA VACCINE; FC RECEPTOR; FREUND ADJUVANT; GLATIRAMER; IMMUNOGLOBULIN; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 10D5; MONOCLONAL ANTIBODY 3D6; MONOCLONAL ANTIBODY AAB 001; MONOCLONAL ANTIBODY M266; POLYSORBATE 80; PRESENILIN 1; PRESENILIN 2; QS 21; SCAVENGER RECEPTOR; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADENOVIRUS VECTOR; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN SIZE; CLINICAL TRIAL; COGNITIVE DEFECT; DOSE RESPONSE; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SAFETY; DRUG TARGETING; ENCEPHALITIS; ENDOCYTOSIS; EPITOPE MAPPING; GENE EXPRESSION; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; INJECTION SITE PAIN; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PASSIVE IMMUNIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; SENILE PLAQUE; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; ANIMALS; HUMANS;

EID: 33750874717     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778793001     Document Type: Review

References (132)

1. Citron M. Alzheimer's disease: treatments in discovery and development. Nature Neurosci Suppl 2002; 5: 1055-7.
2. Collie A, Maruff P. The neuropsychology of preclinical Alzheimer's disease and mild cognitive impairment. Neurosci Biobehav Rev 2000; 24: 365-74.
3. Davis KL, Samuels SC. In: Enna SJ, Coyle JT, editors. Pharmacological Management of Neurological and Psychiatric Disorders. Columbus: McGraw-Hill 1998; 267-316.
4. Selkoe D. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-66.
5. Li Q, Fuller SJ, Beyreuther K, Masters CL. The amyloid precursor protein of Alzheimer disease in human brain and blood. J Leukoc Biol 1999; 66: 567-74.
6. McLaurin J, Yang DS, Yip CM, Fraser PE. Modulating factors in amyloid-β fibril formation. J Struct Biol 2000; 130: 259-70.
7. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, et al. Aβ42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 2005; 47: 191-9.
8. Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW. In vitro aging of amyloid-beta protein causes peptide aggregation and neurotoxicity. Brain Res 1991; 573: 311-4.
9. Lorenzo A, Yankner B. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA 1994; 91: 12243-7.
10. Iversen LL, Mortishire-Sith RJ, Pollack SJ, Shearman MS. The toxicity in vitro of beta-amyloid protein. Biochem J 1995; 311: 1-16.
11. Tsai J, Grutzendler J, Duff K, Gan W. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci 2004; 7: 1181-3.
12. Dodel RC, Hampel H, Du Y. Immunotherapy for Alzheimer's disease. Lancet Neurol 2003; 2: 215-20.
13. Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, et al. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 2000; 283: 1571-7.
14. Terry RD. In: Terry RD, Katzman R, Bick KL, Eds. Alzheimer Disease. Philadelphia: Lippincott Williams and Wilkins 1999; 187-206.
15. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59.
16. Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 1995; 16: 285-98.
17. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999; 46: 860-6.
18. Klein WL, Krafft GA, Finch CE. Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 2001; 24: 219-24.
19. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002; 298: 789-91.
20. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, et al. Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 2003; 100: 10417-22.
21. Georganopoulou DG, Chang L, Nam J, Thaxton CS, Mufson EJ, Klein WL, et al. Nanoparticle-based detetction in cerebralspinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci USA 2004; 102: 2273-6.
22. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 486-89.
23. Walsh DN, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-9.
24. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005; 8: 79-84.
25. St George-Hyslop PH, Tanzi RE, Polinsky RJ, Haines JL, Nee L, Watkins PC, et al. The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science 1987; 235: 885-90.
26. Chartier-Harlin MC, Crawford F, Houlden H, Warren A, Hughes D, Fidani L, et al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 1991; 353: 844-6.
27. Goate A, Chartier-Harlin M, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704-6.
28. Murrell J, Farlow M, Ghetti B, Benson MD. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 1991; 254: 97-9.
29. Hendriks L, van Duijn CM, Cras P, Cruts M, Van Hul W, van Harskamp F, et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet 1992; 1: 218-21.
30. Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta amyloid. Nat Genet 1992; 1: 345-7.
31. Alzheimer's Disease Collaborative Group. The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Nat Genet 1995; 11: 219-22.
32. Campion D, Flaman JM, Brice A, Hannequin D, Dubois B, Martin C, et al. Mutations of the presenilin 1 gene in families with early-onset Alzheimer's disease. Hum Mol Genet 1995; 4: 2373-7.
33. Cruts M, Backhovens H, Wang SY, Van Gassen G, Theuns J, De Jonghe CD, et al. Molecular genetic analysis of familial early-onset Alzheimer's disease linked to chromosome 14q24.3. Hum Mol Genet 1995; 4: 2363-71.
34. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375: 754-60.
35. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995; 376: 775-8.
36. Sherrington R, Froelich S, Sorbi S, Campion D, Chi H, Rogaeva EA, et al. Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet 1996; 5: 985-8.
37. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprtein E: high-avidity binding to β-amyloid and increased frequence of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sci USA 1993; 90: 1977-81.
38. Chapman PF, Falinska AM, Knevett SG, Ramsay MF. Genes, models and Alzheimer's disease. Trends Genet 2001; 17: 254-61.
39. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 2001; 4: 887-93.
40. Chishti MA, Yang D, Janus C, Phinney AL, Horne P, Pearson J, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 2001; 276: 21562-70.
41. Janus C, Pearson J, McLaurin J, Matthews PM, Jiang Y, Schmidt SD, et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000; 408: 979-82.
42. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995; 373: 523-7.
43. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 1996; 274: 99-102.
44. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 1997; 94: 13287-92.
45. 1-42 in wild-type human amyloid protein precursor transgenic mice: synapto-toxicity without plaque formation. J Neurosci 2000; 20: 4050-8.
46. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 2003; 39: 409-21.
47. Dodart J, Mathis C, Bales KR, Paul SM. Does my mouse have Alzheimer's disease? Genes Brain Behav 2002; 1: 142-55.
48. Calhoun ME, Wiederhold JH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, et al. Neuron loss in APP transgenic mice [letter]. Nature 1998; 395: 755-6.
49. Lewis J, Dickson DW, Lin W, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001; 293: 1487-91.
50. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-7.
51. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408: 982-5.
52. Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Desai R, et al. Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PDAPP mice. Ann NY Acad Sci 2000; 920: 328-31.
53. Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, et al. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 2000; 48: 567-79.
54. Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE. Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 2001; 22: 721-7.
55. Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K, et al. β-Amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci 2005; 25: 9096-101.
56. Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, et al. Alzheimer's disease Aβ vaccine reduces central nervous system Aβ levels in a non-human primate, the Caribbean vervet. Am J Pathol 2004; 165: 283-97.
57. Bard F, Cannon C, Barbour R, Burke R, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916-9.
58. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT. Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J Neurosci 2002; 22: 7873-8.
59. Lombardo JA, Stern EA, McLellan ME, Kajdasz ST, Hickey GA, Bacskai BJ, et al. Amyloid-β antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci 2003; 23: 10879-83.
60. Brendza RP, Bacskai BJ, Cirrito JR, Simmons KA, Skoch JM, Klunk WE, et al. Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest 2005; 115: 428-33.
61. DeMattos RB, Bales KR, Cummins DJ, Dodart J, Paul SM, Holtzman DM. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001; 98: 8850-5.
62. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004; 43: 321-2.
63. Ferrari A, Hoerndli F, Baechi T, Nitsch RM, Gotz, J. beta-Amyloid induces paired helical filament-like tau filaments in tissue culture. J Biol Chem 2003; 278: 40162-8.
64. Gotz J, Schild A, Hoerndli F, Pennanen L. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int J Devl Neuroscience 2004; 22: 453-65.
65. Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Abeta42 fibrils. Science 2001; 293: 1491-5.
66. Kulic L, Jurosinski P, Chen F, Tracy J, Mohajeri MH, Li H, et al. Active immunization trial in Abeta(42)-injected P301L tau transgenic mice. Neurobiol Dis 2006; 22: 50-6.
67. Dodart J, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat Neurosci 2002; 5: 452-7.
68. Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, et al. Temporal profile of Aβ oligomerization in an in vivo model of Alzheimer's disease: a link between Aβ and tau pathology. J Biol Chem 2006; 281: 1599-604.
69. Kotilinek A, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 2002; 22: 6331-5.
70. McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, et al. Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 2002; 8: 1263-9.
71. Van Dam D, D'Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De Deyn PP. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci 2003; 17: 388-96.
72. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, et al. Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science 2002; 298: 1379.
73. Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tolnay M, Wiederhold K, et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci USA 1999; 96: 14088-93.
74. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, et al. Passive immunotherapy against abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflamm 2004; 1: 24-35.
75. Racke MM, Boone LI, Hepburn DL, Parasdainian M, Bryan MT, Ness DK, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhages in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid-β. J Neurosci 2005; 25: 629-36.
76. Ujiie M, Dickstein DL, Carlow DA, Jefferies WA. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 2003; 10: 463-70.
77. Wilcock DM, Gordon MN, Ugen KE. Gottschall PE, DiCarlo G, Dickey C, et al. Number of Aβ inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol 2001; 20: 731-6.
78. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J Neurosci 2002; 22: 7873-8.
79. -/- knock-out mice. J Neurosci 2003; 23: 8532-8.
80. Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, et al. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 2003; 23: 3745-51.
81. Lemere CA, Spooner ET, LaFrancois J, Malester B, Mori C, Leverone JF, et al. Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis 2003; 14: 10-8.
82. Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc Natl Acad Sci USA 1996; 93: 452-5.
83. Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc Natl Acad Sci 1997; 94: 4109-12.
84. Frenkel D, Katz O, Solomon B. Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration. Proc Natl Acad Sci 2000; 97: 11455-9.
85. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, et al. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 2003; 100: 2023-8.
86. Paganetti P, Calanca V, Galli C, Stefani M, Molinari M. β-site specific intrabodies to decrease and prevent generation of Alzheimer's Aβ peptide. J Cell Biol 2005; 168: 863-8.
87. Schenk D. Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning. Nature Rev Neurosci 2002; 3: 824-8.
88. Senior K. Dosing in phase II trial of Alzheimer's vaccine suspension. Lancet Neurol 2002; 1: 3.
89. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 2003; 61: 46-54.
90. Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 2003; 9: 448-52.
91. Ferrer I., Rovira MB, Guerra MLS, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer's disease. Brain Pathol 2004; 14: 11-20.
92. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, et al. Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005; 64: 129-31.
93. Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, et al. Aβ42 immunization in Alzheimer's disease generates Aβ N-terminal antibodies. Ann Neurol 2005; 58: 430-5.
94. Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, et al. Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease. Nat Med 2002; 8: 1270-5.
95. Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, et al. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology 2005; 64: 94-101.
96. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Müller-Tilmanns B, et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38: 547-54.
97. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, et al. Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005; 64: 1563-72.
98. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64: 1553-62.
99. Schenk D, Hagen M, Seubert P. Current progress in beta-amyloid immunotherapy. Curr Opin Immunol 2004; 16: 1-8.
100. Furlan R, Brambilla E, Sanvito F, Roccatagliata L, Olivieri S, Bergami A, et al. Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57BL/6 mice. Brain 2003; 126: 285-91.
101. Bowers WJ, Mastrangelo MA, Stanley HA, Casey AE, Milo LJ, Federoff HJ. HSV amplicon-mediated Abeta vaccination in the Tg2576 mice: differential antigen-specific immune responses. Neurobiol Aging 2005; 26: 393-407.
102. Lee EB, Leng LZ, Lee VM, Trojanowski JQ. Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis. FEBS Lett 2005; 579: 2564-8.
103. Frenkel D, Maron R, Burt DS, Weiner HL. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears β-amyloid in a mouse model of Alzheimer's disease. J Clin Invest 2005; 115: 2423-33.
104. Weiner HL, Selkoe DJ. Inflammation and therapeutic vaccination in CNS diseases. Nature 2002; 420: 879-84.
105. Grubeck-Loebenstein B, Blasko I, Marx F, Trieb K. Immunization with β-amyloid: could T-cell activation have a harmful effect? TINS 2000; 23: 114.
106. Monsonego A, Maron R, Zota V, Selkoe DJ, Weiner HL. Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci USA 2003; 98: 10273-8.
107. Pride MW, Black RS, Hagen M, Dispoto S, Souza V, Giorgio D, et al. Evaluation of the cellular immune response in AD patients after immunotherapy with AN1792(QS-21). Neurobiol Aging 2004; 25: 574.
108. (1-42) immunotherapy in preimmunization gene expression patterns of blood cells. Arch Neurol 2005; 62: 1531-6.
109. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T. Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 2001; 159: 439-47.
110. Leverone JF, Spooner ET, Lehman HK, Clements JD, Lemere CA. Abeta1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting." Vaccine 2003; 21: 2197-206.
111. Agadjanyan MG, Ghochikyan A, Petrushina A, Vasilevko V, Movsesyan N, Mkrtichyan M, et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 2005; 174: 1580-6.
112. Spinney L. Update on Elan vaccine for Alzheimer's disease. Lancet Neurol 2004; 3: 5 (lett.).
113. Farina C, Weber MS, Meinl E, Wekerle H, Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol 2005; 4: 567-75.
114. DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D. Intra-hippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiol Aging 2001; 22: 1007-12.
115. Herber DL, Roth LM, Wilson D, Wilson N, Mason JE, Morgan D, et al. Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp Neurol 2004; 190: 245-53.
116. Sheng JG, Bora SH, Xu G, Borchelt DR, Price DL, Koliatsos VE. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol Dis 2003; 14: 133-45.
117. Neuroinflammation Working Group. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383-421.
118. Monsonego A, Imitola J, Zota V, Oida T, Weiner HL. Microglia-mediated nitric oxide cytotoxicity of T cells following amyloid beta-peptide presentation to Th1 cells. J Immunol 2003; 171: 2216-24.
119. Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N, et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 2003; 15: 505-14.
120. Zhang J, Wu X, Qin C, Qi J, Ma S, Zhang H, et al. A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease. Neurobiol Dis 2003; 14: 365-79.
121. Ghochikyan A, Vasilevko V, Petrushina I, Movsesyan N, Baibkyan D, Tian W, et al. Generation and characterization of the humoral immune response to DNA immunization with a chimeric betaamyloid-interleukin-4 minigene. Eur J Immunol 2003; 33: 3232-41.
122. Kim HD, Kong FK, Cao Y, Lewis TL, Kim H, Tang DC, et al. Immunization of Alzheimer model mice with adenovirus vectors encoding amyloid beta-protein and GM-CSF reduces amyloid load in the brain. Neurosci Lett 2004; 370: 218-23.
123. Qu B, Rosenberg RN, Li L, Boyer PJ, Johnston SA. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol 2004; 61: 1859-64.
124. Schiltz JG, Salzer U, Mohajeri MH, Franke D, Heinrich J, Pavlovic J, et al. Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease. J Mol Med 2004; 82: 706-14.
125. Youm JW, Kim H, Lo Han JH, Jang CH, Ha HJ, Mook-Jung I, et al. Transgenic potato expressing Abeta reduce Abeta burden in Alzheimer's disease mouse model. FEBS Lett 2005; 579: 6737-44.
126. Elan Corporation. Elan: Alzheimer's Research [online]. 2005 [cited 2005 Dec 7]. Available from: http://www.elan.com/research_development/ Alzheimers/
127. Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004; 75: 1472-4.
128. Du Y, Wei X, Dodel R, Sommer N, Hampel H, Gao F, et al. Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 2003; 126: 1935-9.
129. Rangan SK, Ruitian L, Brune D, Planque S, Paul S, Sierks MR. Degradation of β-amyloid by proteolytic antibody light chains. Biochemistry 2003; 42: 14328-34.
130. Ancelin ML, Ritchie K. Lifelong endocrine fluctuations and related cognitive disorders. Curr Pharm Des 2005; 11(32): 4229-52.
131. Bernardo A, Minghetti L. PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr Pharm Des 2006; 12(1): 93-109.
132. Nelson RB. The dualistic nature of immune modulation in Alzheimer's disease: lessons from the transgenic models. Curr Pharm Des 2005; 11(26): 3335-52.